<!DOCTYPE html SYSTEM "about:legacy-compat">
<html lang="en-US" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <title>Chapter 05 Medical Laboratories — Proficiency Testing | Library of Maryland Regulations</title>
    <link rel="shortcut icon" href="/us/md/exec/_document/v2/images/favicons/favicon.ico"/>
    <!--Meta-->
    <meta http-equiv="X-UA-Compatible" content="IE=EDGE"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>
    <meta name="format-detection" content="telephone=no"/>
    <meta name="HandheldFriendly" content="true"/>
    <meta itemprop="full-html" content="/us/md/exec/comar/10.10.05/index.full.html" data-document="href"/>
    <meta itemprop="toc-json" content="/us/md/exec/comar/10.10.05/index.json" data-document="href"/>
    <meta itemprop="parent-doc-url" content="/us/md/exec/comar" data-document="href"/>
    <meta itemprop="order" content="|10|10|05|"/>
    <meta itemprop="doc-type" content="container" data-document=""/>
    <meta itemprop="doc-num" content="05"/>
    <meta itemprop="ref-doc" content="Code of Maryland Regulations" data-document=""/>
    <meta itemprop="ref-path" content="10|10|05" data-document=""/>
    <!--OpenGraph-->
    <meta property="og:url" content="http://regs.maryland.gov//us/md/exec/comar/10.10.05"/>
    <meta property="og:type" content="article"/>
    <meta property="og:title" content="Chapter 05 Medical Laboratories — Proficiency Testing | Library of Maryland Regulations"/>
    <meta property="og:image" content="http://regs.maryland.gov//us/md/exec/_document/v2/images/og/og_image.png"/>
    <!--Progressive Web App-->
    <link rel="manifest" href="/manifest.json"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="apple-mobile-web-app-status-bar-style" content="#0078EF"/>
    <meta name="apple-mobile-web-app-title" content="Library of Maryland Regulations"/>
    <meta name="theme-color" content="#0078EF"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="mobile-web-app-capable" content="yes"/>
    <!--PWA icons-->
    <link rel="apple-touch-icon" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-60x60-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-76x76-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-152x152-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-180x180-precomposed.png"/>
    <link rel="mask-icon" href="/us/md/exec/_document/v2/images/favicons/safari-pinned-tab.svg" color="#0078EF"/>
    <link rel="icon" type="image/png" sizes="16x16" href="/us/md/exec/_document/v2/images/favicons/favicon-16x16.png"/>
    <link rel="icon" type="image/png" sizes="32x32" href="/us/md/exec/_document/v2/images/favicons/favicon-32x32.png"/>
    <link rel="icon" type="image/png" sizes="48x48" href="/us/md/exec/_document/v2/images/favicons/favicon-48x48.png"/>
    <!--Fonts-->
    <link href="/us/md/exec/_document/v2/biticons/biticons.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/public-sans/public-sans.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/merriweather/merriweather.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/roboto-mono/roboto-mono.css" type="text/css" rel="stylesheet" data-document=""/>
    <!--Document CSS-->
    <link href="/us/md/exec/_document/v2/styles/responsive.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/main.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/print.min.css" type="text/css" rel="stylesheet" media="print" data-document=""/>
    <link href="/_reader/styles/main.min.css" type="text/css" rel="stylesheet"/>
    <script src="/_reader/js/main.js" data-document=""> </script>
    <!--Links to resources that need to be prefetched-->
    <link rel="prefetch" href="/us/md/exec/comar/10.10.05/index.full.html" as="fetch"/>
    <link rel="prefetch" href="/index.json" as="fetch"/>
    <link rel="prefetch" href="/us/md/exec/comar/10.10.05/index.json" as="fetch"/>
  </head>
  <body>
    <div role="region" id="announcer" aria-live="polite" class="sr-only" aria-atomic="true" aria-label="Live messages">
      <p id="message"> </p>
    </div>
    <nav class="visually-hidden">
      <a href="#area__content" class="skip-link">Skip to main content</a>
    </nav>
    <div id="grid" class="ns__document__maryland-dsd">
      <header id="section__header" class="ns__document__maryland-dsd">
        <div id="section__header__inner" class="ns__document__maryland-dsd">
          <div id="area__logo" class="ns__document__maryland-dsd">
            <a href="/" class="logo" aria-label="Logo - Return to library home page">
              <img src="/us/md/exec/_document/v2/images/logo/logo.png" srcset="/us/md/exec/_document/v2/images/logo/logo.png 1x, /us/md/exec/_document/v2/images/logo/logo@2x.png 2x, /us/md/exec/_document/v2/images/logo/logo@3x.png 3x" alt="Library of Maryland Regulations logo"/>
            </a>
          </div>
          <div id="area__main_title" class="ns__document__maryland-dsd">
            <div class="h__library-logotype"><span class="line1">Library of</span> <span class="line2">Maryland Regulations</span></div>
          </div>
        </div>
      </header>
      <div id="section__content" class="ns__document__maryland-dsd">
        <div id="section__content__inner" class="ns__document__maryland-dsd">
          <section id="area__breadcrumbs" class="ns__document__maryland-dsd" role="region" aria-label="Breadcrumbs">
            <input type="checkbox" id="menu-trigger" class="menu-trigger" aria-label="Mobile menu toggler"/>
            <label for="menu-trigger">
              <span class="visually-hidden">Toggle mobile menu</span>
            </label>
            <nav role="navigation" aria-label="Breadcrumb navigation">
              <div class="h__ui">Navigation</div>
              <ul class="ancestors">
                <li data-search-path="library" data-search-heading="All Documents" class="no-indent">
                  <a href="/" title="Library of Maryland Regulations">Library of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations" data-search-heading="" data-search-default="true" class="li__book-open">
                  <a href="/us/md/exec/comar" title="Code of Maryland Regulations">Code of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10" data-search-heading="">
                  <a href="/us/md/exec/comar/10" title="Title 10 MARYLAND DEPARTMENT OF HEALTH">Title 10 MARYLAND DEPARTMENT OF HEALTH</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|10" data-search-heading="">
                  <a href="/us/md/exec/comar/10.10" title="Subtitle 10 LABORATORIES">Subtitle 10 LABORATORIES</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|10|05" data-search-heading="">
                  <span title="Chapter 05 Medical Laboratories — Proficiency Testing">Chapter 05 Medical Laboratories — Proficiency Testing</span>
                </li>
              </ul>
            </nav>
          </section>
          <main id="area__content" class="ns__document__maryland-dsd">
            <div class="h__document-title">Code of Maryland Regulations</div>
            <article class="content" role="document" data-ref-path="10|10|05">
              <div class="tuf-authenticate">
                <h1 class="h__toc" id="/us/md/exec/comar/10.10.05">Chapter 05 Medical Laboratories — Proficiency Testing</h1>
                <section class="line-group annotations">
                  <h2>Administrative History</h2>
                  <p>Effective date: October 5, 1998 (25:20 Md. R. 1529)</p>
                  <p>——————</p>
                  <p>Chapter, Job-Related Alcohol and Controlled Dangerous Substances Testing, repealed and new chapter, Medical Laboratories—Proficiency Testing, adopted effective December 13, 1999 (26:25 Md. R. 1897)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05.01" title=".01 Participation and Evaluation.">Regulation .01</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05.02#B" title="">Regulation .02B</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05.03" title=".03 Program Approval.">Regulation .03</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05.04" title=".04 Cytology — Departmental Requirements.">Regulation .04</a> amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05.04#D" title="">Regulation .04D</a> amended effective November 29, 2010 (37:24 Md. R. 1658)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05.05#B" title="">Regulation .05B</a>, C amended effective June 1, 2009 (36:11 Md. R. 787)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.10.05.05#C" title="">Regulation .05C</a> amended effective November 29, 2010 (37:24 Md. R. 1658)</p>
                  <h2>Authority</h2>
                  <p>Health-General Article, §§17-202 and 17-211, Annotated Code of Maryland</p>
                </section>
                <h2 id="/us/md/exec/comar/10.10.05.01" data-order="|10|10|05|.01|" data-ref-path="10|10|05|.01" class="h__section">.01 Participation and Evaluation.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#A">A.</span> Participation. A licensee operating under a permit shall ensure that the laboratory:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#A(1)">(1)</span> Enrolls in and participates satisfactorily in a PT program that meets the criteria set forth in this chapter for each of the tests that the laboratory offers to perform or performs;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#A(2)">(2)</span> Tests PT samples in the same manner and number of times that it routinely tests patient specimens; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#A(3)">(3)</span> Complies with the applicable standards contained in 42 CFR §§493.801—493.807.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#B">B.</span> Evaluation — General. When a PT program does not evaluate a participating laboratory's PT results or the evaluated PT results are inconsistent with satisfactory performance, the participating laboratory and the OHCQ shall evaluate the PT results by comparing them to the all-method-results mean, all-instrument-results mean, or the all-participant-results mean found in the PT program's summaries of PT results.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C">C.</span> Evaluation — Departmental.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)">(1)</span> Administrative Procedures.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(a)">(a)</span> Submission of Results. The OHCQ shall monitor for regulatory purposes only official results sent directly from the PT program.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(b)">(b)</span> Multiple Programs. If a licensee enrolls in more than one PT program and duplicate testing and reporting occurs, the licensee shall notify the OHCQ which PT program is to be scored for regulatory purposes.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(c)">(c)</span> Sample Testing. A licensee shall operate under the following PT procedures:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(c)(i)">(i)</span> PT samples shall be tested each time a shipment is received and for only those procedures offered or allowed under a laboratory's license;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(c)(ii)">(ii)</span> If a test is no longer offered or performed, the licensee shall inform the OHCQ in writing;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(c)(iii)">(iii)</span> PT samples shall be tested only in the laboratory for which they are intended;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(c)(iv)">(iv)</span> PT samples shall be handled, processed, and tested in the same manner as patient specimens; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(c)(v)">(v)</span> Repeat testing may not be performed on PT samples unless it is the laboratory's policy to test patients in duplicate or if abnormal test results are routinely repeated to verify accuracy.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(d)">(d)</span> Testing and Reporting Deadlines.</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(d)(i)">(i)</span> A licensee shall test PT samples and report PT results within the time limits set by the PT program.</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(d)(ii)">(ii)</span> PT results submitted late by a licensee are deemed unsatisfactory by the PT program and the OHCQ.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(e)">(e)</span> PT Program Evaluation Errors. A licensee is responsible for seeing that an evaluation error on the PT report is corrected by the PT program and that the program sends a corrected PT report to the OHCQ.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(f)">(f)</span> Performance Records. A laboratory's marginal or unsatisfactory PT performance may not be changed to reflect satisfactory performance when:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(f)(i)">(i)</span> PT results are not submitted;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(f)(ii)">(ii)</span> PT results are submitted after the due date; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(1)(f)(iii)">(iii)</span> Transcription errors involving PT results went unnoticed until the evaluated results were scored.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)">(2)</span> Evaluation Procedures.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(a)">(a)</span> Grading Criteria.</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(a)(i)">(i)</span> The PT program shall score test results in terms of correlation with reference or referee laboratory test results, target values, or statistical methods based on means and standard deviations.</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(a)(ii)">(ii)</span> The OHCQ shall determine a laboratory's PT performance based on a PT program's numerical score for each specialty, subspecialty, constituent, analyte, and culture type.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)">(b)</span> Scores. Numerical PT scores required for satisfactory performance in each subdiscipline, specialty or subspecialty are as follows:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(i)">(i)</span> AFP for NTD, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(ii)">(ii)</span> Antibodies for HIV, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(iii)">(iii)</span> Bacteriology, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(iv)">(iv)</span> Blood gases, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(v)">(v)</span> Blood lead, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(vi)">(vi)</span> Chemistry, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(vii)">(vii)</span> Coagulation, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(viii)">(viii)</span> Cytogenetics, as set by PT program;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(ix)">(ix)</span> Drugs of abuse, forensic, equal to or greater than 90 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(x)">(x)</span> Drugs of abuse, clinical or diagnostic, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(xi)">(xi)</span> Hematology, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(xii)">(xii)</span> Immunohematology, ABO and Rh typing, antibody screen, 100 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(xiii)">(xiii)</span> Immunohematology, antibody identification, equal to or greater than 90 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(xiv)">(xiv)</span> Mycology, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(xv)">(xv)</span> Mycobacteriology, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(xvi)">(xvi)</span> Immunology, nonsyphilis serology, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(xvii)">(xvii)</span> Parasitology, equal to or greater than 80 percent;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(xviii)">(xviii)</span> Syphilis serology, equal to or greater than 80 percent; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(b)(xix)">(xix)</span> Urinalysis, equal to or greater than 80 percent.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(c)">(c)</span> Scoring Criteria. A percent score is derived by dividing the number of satisfactory PT results by the total number of PT results for each subdiscipline, specialty, subspecialty, or individual constituent or analyte within a subspecialty.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(d)">(d)</span> PT Failure. PT scores lower than the percent scores listed in <a class="internal-link " href="/us/md/exec/comar/10.10.05.01#C(2)(b)" title="">§C(2)(b) of this regulation</a> are failing scores.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(2)(e)">(e)</span> Evaluated PT Results. PT results evaluated in determining PT performance include PT results not evaluated by the PT program, code 10 results, for example, 10E, 10G, 10T, and codes of tests not performed.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(3)">(3)</span> Initial or Single PT Failure.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(3)(a)">(a)</span> Licensee Action. A licensee shall investigate a single or initial PT failure and document the corrective action taken.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(3)(b)">(b)</span> Departmental Procedures. The OHCQ shall document an initial or single PT failure and may request a licensee to submit a plan of correction and supporting documentation related to the failure.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(4)">(4)</span> Marginal PT Performance.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(4)(a)">(a)</span> Test Scores. PT performance is marginal when a laboratory exhibits failing PT scores in two of three consecutive testing events in a subdiscipline, specialty, subspecialty, or individual constituent or analyte, for example, Na, RBC, cholesterol.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(4)(b)">(b)</span> Departmental Procedures. The OHCQ shall:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(4)(b)(i)">(i)</span> Document the marginal PT;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(4)(b)(ii)">(ii)</span> Send written notice of the marginal PT to the licensee; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(4)(b)(iii)">(iii)</span> Request the licensee to submit a written plan of correction.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(4)(c)">(c)</span> Laboratory Actions. A licensee shall submit to the OHCQ a written plan of correction that describes the investigation and steps taken to improve the applicable test performance.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(5)">(5)</span> Unsatisfactory PT Performance. PT performance is unsatisfactory when a laboratory exhibits:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(5)(a)">(a)</span> Failing PT scores in three of four consecutive testing events in a subdiscipline, specialty, or individual constituent or analyte, for example, Na, RBC, cholesterol;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(5)(b)">(b)</span> Failing PT scores in two of three consecutive testing events in a subdiscipline, specialty, subspecialty, or individual constituent or analyte, for example, Na, RBC, cholesterol, and the next PT report for the test states "test not performed"; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.01#C(5)(c)">(c)</span> An average PT score for a test over the last four consecutive testing events that falls below the minimum percent score set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.05.01#C(2)(b)" title="">§C(2)(b) of this regulation</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.05.02" data-order="|10|10|05|.02|" data-ref-path="10|10|05|.02" class="h__section">.02 Discipline, Specialty, and Subspecialty.</h2>
                <div class="message message--info" role="region" tabindex="0" aria-label="Warning">
                  <div class="h__message">Pending Changes</div>
                  <p>This section will be changed by the following pending documents:</p>
                  <ul>
                    <li>March 1, 2026: <a href="/us/md/exec/register/52/24">Maryland Register, Volume 52, Issue 24</a></li>
                  </ul>
                </div>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A">A.</span> Primary Standard. A licensee operating under a permit shall ensure that the laboratory participates successfully in PT, when applicable, for each test or analyte in each of the following disciplines, subdisciplines, and specialties:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(1)">(1)</span> Microbiology, including the subdisciplines of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(1)(a)">(a)</span> Bacteriology;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(1)(b)">(b)</span> Mycobacteriology;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(1)(c)">(c)</span> Mycology;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(1)(d)">(d)</span> Parasitology; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(1)(e)">(e)</span> Virology;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(2)">(2)</span> Immunology, including the subdisciplines of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(2)(a)">(a)</span> General immunology;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(2)(b)">(b)</span> General serology; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(2)(c)">(c)</span> Syphilis serology;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(3)">(3)</span> Chemistry, including the subdisciplines of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(3)(a)">(a)</span> Blood gas analysis;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(3)(b)">(b)</span> Endocrinology;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(3)(c)">(c)</span> Routine chemistry; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(3)(d)">(d)</span> Toxicology;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(4)">(4)</span> Genetics, including the subdisciplines of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(4)(a)">(a)</span> Biochemical genetics;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(4)(b)">(b)</span> Cytogenetics; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(4)(c)">(c)</span> Molecular genetics;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(5)">(5)</span> Hematology, including the subdisciplines of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(5)(a)">(a)</span> Coagulation testing; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(5)(b)">(b)</span> Routine hematology;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(6)">(6)</span> Pathology, including the subdiscipline of gynecologic cytology;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(7)">(7)</span> Immunohematology, including the specialties of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(7)(a)">(a)</span> ABO group and D(Rho) typing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(7)(b)">(b)</span> Unexpected antibody detection, that is, antibody screen;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(7)(c)">(c)</span> Antibody identification; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(7)(d)">(d)</span> Compatibility testing; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#A(8)">(8)</span> Forensic toxicology limited to job-related alcohol and controlled dangerous substances.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B">B.</span> Discipline Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(1)">(1)</span> General. A licensee operating under a permit shall ensure that the laboratory meets the applicable PT standards set forth in this chapter and in 42 CFR §§493.821 — 493.865.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(2)">(2)</span> Gynecologic Cytology. A licensee operating under a permit to perform gynecologic cytology shall ensure that the laboratory enrolls and maintains successful participation in:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(2)(a)">(a)</span> A cytology PT program operated by the Secretary if the laboratory is located inside this State; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(2)(b)">(b)</span> A cytology PT program approved by CMS if the laboratory is located outside this State.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)">(3)</span> Job-Related Testing.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(a)">(a)</span> A licensee operating under a permit to perform job-related testing for alcohol or controlled dangerous substances shall ensure that the laboratory enrolls and continues to participate satisfactorily, when applicable, in one or more of the programs listed in §B(3)(b)—(e) of this regulation.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(b)">(b)</span> Screening Tests. A licensee operating under a permit to perform screening tests for job-related alcohol and controlled dangerous substances shall ensure that the laboratory enrolls and participates satisfactorily in:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(b)(i)">(i)</span> The American Association of Bioanalysts (AAB) Urine Toxicology Screening survey;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(b)(ii)">(ii)</span> The American Association for Clinical Chemistry/College of American Pathologists (AACC/CAP) Forensic Urine Drug Testing Screening survey; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(b)(iii)">(iii)</span> Another program approved by the Secretary as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.05.03" title=".03 Program Approval.">Regulation .03 of this chapter</a>.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(c)">(c)</span> Confirmation Tests. A licensee operating under a permit to perform confirmation tests for job-related alcohol and controlled dangerous substances shall ensure that the laboratory enrolls and participates satisfactorily in:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(c)(i)">(i)</span> The AACC/CAP Forensic Urine Drug Testing Confirmatory survey;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(c)(ii)">(ii)</span> The federal Substance Abuse and Mental Health Services Administration's Federal Workplace Drug Testing Program; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(c)(iii)">(iii)</span> Another program approved by the Secretary as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.05.03" title=".03 Program Approval.">Regulation .03 of this chapter</a>.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(d)">(d)</span> Blood Alcohol Tests. A licensee operating under a permit to perform tests for alcohol in blood shall ensure that the laboratory enrolls and participates satisfactorily in:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(d)(i)">(i)</span> The AACC/CAP survey for whole blood alcohol or serum alcohol, or both; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(d)(ii)">(ii)</span> Another program approved by the Secretary as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.05.03" title=".03 Program Approval.">Regulation .03 of this chapter</a>.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(e)">(e)</span> Hair Analysis. A licensee operating under a permit to perform tests for a controlled dangerous substance in hair shall ensure that the laboratory enrolls and participates satisfactorily in:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(e)(i)">(i)</span> The State of Florida's P.T. program for drug testing in hair; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.02#B(3)(e)(ii)">(ii)</span> Another program that possesses standards set by the Secretary or that are equivalent to the State of Florida's PT program for drug testing in hair and is approved by the Secretary as set forth in <a class="internal-link " href="/us/md/exec/comar/10.10.05.03" title=".03 Program Approval.">Regulation .03 of this chapter</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.05.03" data-order="|10|10|05|.03|" data-ref-path="10|10|05|.03" class="h__section">.03 Program Approval.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.03#A">A.</span> Approval Required. A private, nonprofit, or commercial organization or government agency may not provide a PT program in this State without first obtaining program approval from CMS or the OHCQ.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.03#B">B.</span> Approval Granted Automatically. Except in the discipline of job-related alcohol and controlled dangerous substances, or other disciplines, subdisciplines, or specialties not covered by federal PT requirements, a PT program is approved when it is based on written evidence issued by CMS showing the program meets CMS's criteria for approval of PT programs as set forth in 42 CFR §§493.901—493.959.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.03#C">C.</span> Approval Granted by the Secretary. The OHCQ may approve a PT program for a laboratory discipline, subdiscipline, or specialty not approved by CMS, if the program:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.03#C(1)">(1)</span> Provides reliable, documented evidence that the program is technically and administratively able to meet the applicable requirements of this chapter; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.03#C(2)">(2)</span> Uniformly and routinely prepares and submits directly to the OHCQ evaluations of all PT results from all laboratories enrolled in the program and holding a Maryland permit.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.05.04" data-order="|10|10|05|.04|" data-ref-path="10|10|05|.04" class="h__section">.04 Cytology — Departmental Requirements.</h2>
                <div class="message message--info" role="region" tabindex="0" aria-label="Warning">
                  <div class="h__message">Pending Changes</div>
                  <p>This section will be changed by the following pending documents:</p>
                  <ul>
                    <li>March 1, 2026: <a href="/us/md/exec/register/52/24">Maryland Register, Volume 52, Issue 24</a></li>
                  </ul>
                </div>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#A">A.</span> The Secretary may not issue a license to operate a laboratory that examines gynecologic cytology specimens if the laboratory does not enroll and participate satisfactorily in a cytology PT program operated or approved by the Secretary.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#B">B.</span> The OHCQ shall conduct annual PT for each pathologist and cytotechnologist who examines gynecological cytology slides acquired in the State.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#C">C.</span> The OHCQ or an agent of the Department shall hand carry test materials for first-event testing in a PT cycle to a laboratory and shall conduct and supervise all testing.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#D">D.</span> The OHCQ shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#D(1)">(1)</span> Conduct announced and unannounced on-site testing for individuals during an annual PT cycle; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#D(2)">(2)</span> Schedule and conduct a retesting event for an individual who has failed the annual PT testing event not more than 45 days after receipt of the notification of the PT testing event failure by the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#D(2)(a)">(a)</span> Individual who failed the annual PT testing event; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#D(2)(b)">(b)</span> Laboratory director of the individual who failed the annual PT testing event.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#E">E.</span> The OHCQ may conduct unannounced PT at any time during normal laboratory working hours when the testing is conducted as part of routine PT, a complaint investigation, a follow-up certification, or a regulatory compliance survey.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#F">F.</span> The OHCQ shall conduct announced retesting within an annual PT cycle at a site selected by the Department.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#G">G.</span> The OHCQ shall schedule an individual who misses a laboratory's annual PT event to make up the missed test.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.04#H">H.</span> The OHCQ shall evaluate an individual's PT performance as set forth in 42 CFR §493.945.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.10.05.05" data-order="|10|10|05|.05|" data-ref-path="10|10|05|.05" class="h__section">.05 Cytology — Laboratory and Individual Standards.</h2>
                <div class="message message--info" role="region" tabindex="0" aria-label="Warning">
                  <div class="h__message">Pending Changes</div>
                  <p>This section will be changed by the following pending documents:</p>
                  <ul>
                    <li>March 1, 2026: <a href="/us/md/exec/register/52/24">Maryland Register, Volume 52, Issue 24</a></li>
                  </ul>
                </div>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#A">A.</span> Primary Standard. A pathologist or cytotechnologist who examines gynecological cytology specimens from individuals in this State shall participate satisfactorily in an annual cytology PT program approved by the Secretary.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B">B.</span> Laboratory Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B(1)">(1)</span> A licensee operating under a permit to examine gynecologic cytology specimens shall ensure that each pathologist and cytotechnologist who examines gynecologic cytology specimens participates in a cytology PT program conducted by the Department or approved by the Secretary.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B(2)">(2)</span> An in-State laboratory shall participate in the Department's PT program.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B(3)">(3)</span> An out-of-State laboratory shall participate in either the Department's PT program or another equivalently rigorous cytology PT program approved by the Secretary.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B(4)">(4)</span> A licensee employing an individual who has failed a second testing event in an annual PT cycle shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B(4)(a)">(a)</span> Prohibit the individual from examining gynecologic specimens and provide or secure remedial training and education in gynecologic cytology for the individual, which training and education includes examination by the individual of gynecologic specimens in the individual's area of failure; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B(4)(b)">(b)</span> Document the individual's completion of education and training using a form provided by the OHCQ.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B(5)">(5)</span> A licensee employing an individual who has failed a first or subsequent PT event and who does not obtain mandated retesting or retraining, or both, shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B(5)(a)">(a)</span> Immediately remove that individual from a position of examining gynecologic cytology specimens for the purpose of reporting diagnostic test results to a health care provider; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#B(5)(b)">(b)</span> Provide written notice to the OHCQ within 30 days after being informed of the individual's last test failure that the individual is no longer examining gynecologic cytology specimens for the purpose of reporting diagnostic test results to a health care provider.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C">C.</span> Individual Standards.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(1)">(1)</span> A cytotechnologist or pathologist who examines gynecological cytology specimens shall participate in an annual PT event that involves the examination of a 10-slide or 20-slide test set as set forth in 42 CFR §493.945.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(2)">(2)</span> An individual passes a testing event and performs satisfactorily in PT when the individual scores at least 90 percent on a 10-slide or 20-slide test set.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(3)">(3)</span> An individual fails a testing event and performs unsatisfactorily in PT if the individual:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(3)(a)">(a)</span> Scores less than 90 percent on a 10-slide or 20-slide test set; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(3)(b)">(b)</span> Fails to take a scheduled retest without prior Department approval.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(4)">(4)</span> An individual who fails the annual testing event shall take a second test with another 10-slide test set:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(4)(a)">(a)</span> Within 45 days after receiving notice of a test failure; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(4)(b)">(b)</span> At a later date with prior Department approval.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(5)">(5)</span> An individual who fails a second test shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(5)(a)">(a)</span> Cease examining gynecologic specimens immediately upon being notified of the second failure;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(5)(b)">(b)</span> Complete at least 40 hours of remedial training and education in gynecologic cytology that includes examining gynecological specimens in the area of failure;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(5)(c)">(c)</span> Complete the required training and education in a laboratory that operates under a:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(5)(c)(i)">(i)</span> State permit for in-State laboratories; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(5)(c)(ii)">(ii)</span> Certificate issued by CMS in the subdiscipline of gynecologic cytology for out-of-State laboratories;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(5)(d)">(d)</span> Document the required remedial training and education when completed, using a form provided by the OHCQ, and submit the completed form to the OHCQ;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(5)(e)">(e)</span> Schedule and take a third test with a 20-slide test set within 30 days of completing the required remedial training and education; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(5)(f)">(f)</span> Begin examining gynecologic cytology specimens only after the OHCQ informs the individual that the individual obtained a passing score on the third test.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(6)">(6)</span> An individual who fails a third or subsequent test shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(6)(a)">(a)</span> Complete at least 35 hours of documented, formally structured, continuing education in diagnostic cytopathology that focuses on the examination of gynecologic preparations;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(6)(b)">(b)</span> Document the education when completed, using a form provided by the OHCQ, and submit the completed form to the OHCQ;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(6)(c)">(c)</span> Schedule and take a subsequent test with a 20-slide test set within 30 days of completing the required continuing education; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(6)(d)">(d)</span> Begin examining gynecologic cytology specimens only after the OHCQ informs the individual that the individual obtained a passing score on the test required under <a class="internal-link " href="/us/md/exec/comar/10.10.05.05#C(6)(c)" title="">§C(6)(c) of this regulation</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(7)">(7)</span> An individual who fails a first or subsequent testing event in an annual PT cycle and who chooses not to complete mandatory retesting or remedial training, or both, shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(7)(a)">(a)</span> Immediately cease examining gynecologic cytology specimens and notify the OHCQ of this in writing; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.10.05.05#C(7)(b)">(b)</span> Reenter the PT process at the point where the individual previously chose to withdraw from the testing process, if the individual decides at a later date to satisfy PT requirements.</p>
                <hr class="section-separator" aria-hidden="true"/>
              </div>
            </article>
          </main>
          <nav id="area__navigation_mini" class="ns__document__maryland-dsd" aria-label="Previous and next article links">
            <section>
              <a href="/us/md/exec/comar/10.10.04" aria-label="Chapter 04 Medical Laboratories">
                <div class="h__ui">Previous</div>
                <span>Chapter 04 Medical Laboratories</span>
              </a>
            </section>
            <section>
              <a href="/us/md/exec/comar/10.10.06" aria-label="Chapter 06 Medical Laboratories — Quality Assurance">
                <div class="h__ui">Next</div>
                <span>Chapter 06 Medical Laboratories — Quality Assurance</span>
              </a>
            </section>
          </nav>
        </div>
      </div>
      <footer id="section__footer" class="ns__document__maryland-dsd">
        <div id="section__footer__inner" class="ns__document__maryland-dsd">
          <div id="area__footer__content" class="ns__document__maryland-dsd">
<p>This version of the laws and codes on this website is licensed under the <a href="https://creativecommons.org/licenses/by-nc-sa/4.0/">CC BY-NC-SA 4.0</a> license with copyright held by the State of Maryland.</p><p>This version of the laws and codes on this website will be dedicated to the public domain under the <a href="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0</a> license 180 days after publication.</p>
<p>
      Please do not scrape. Instead, bulk download the CC BY-NC-SA-4.0 <a href="https://github.com/maryland-dsd/law-html">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml">XML</a> or CC0 <a href="https://github.com/maryland-dsd/law-html-cc0">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml-cc0">XML</a>.
    </p><p>Powered by the non-profit <a href="https://www.openlawlib.org/">Open Law Library</a>.</p></div>
        </div>
      </footer>
    </div>
    <!--Piwik analytics-->
    <noscript>
      <img src="/_analytics/pixel.png" style="border:0;" alt=""/>
    </noscript>
  </body>
</html>
